Analysts forecast that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will announce earnings per share (EPS) of ($0.07) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for AcelRx Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.09). AcelRx Pharmaceuticals posted earnings of ($0.16) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 56.3%. The business is expected to report its next quarterly earnings results on Wednesday, November 4th.

On average, analysts expect that AcelRx Pharmaceuticals will report full-year earnings of ($0.44) per share for the current year, with EPS estimates ranging from ($0.51) to ($0.39). For the next financial year, analysts expect that the business will report earnings of ($0.28) per share, with EPS estimates ranging from ($0.45) to ($0.17). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Monday, August 10th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. The company had revenue of $2.92 million for the quarter, compared to analyst estimates of $3.90 million.

Several research firms recently commented on ACRX. Credit Suisse Group raised their price target on shares of AcelRx Pharmaceuticals from $0.69 to $0.84 and gave the stock an “underperform” rating in a report on Thursday, August 13th. Zacks Investment Research cut shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $4.34.

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its position in shares of AcelRx Pharmaceuticals by 5.7% in the 1st quarter. Geode Capital Management LLC now owns 1,153,393 shares of the specialty pharmaceutical company’s stock valued at $1,361,000 after acquiring an additional 62,709 shares during the period. BlackRock Inc. boosted its holdings in shares of AcelRx Pharmaceuticals by 0.9% in the 1st quarter. BlackRock Inc. now owns 5,659,788 shares of the specialty pharmaceutical company’s stock valued at $6,678,000 after buying an additional 47,771 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in shares of AcelRx Pharmaceuticals in the 2nd quarter valued at approximately $48,000. Wells Fargo & Company MN boosted its holdings in shares of AcelRx Pharmaceuticals by 19.4% in the 1st quarter. Wells Fargo & Company MN now owns 215,809 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 35,003 shares during the last quarter. Finally, State Street Corp lifted its holdings in AcelRx Pharmaceuticals by 2.5% during the 1st quarter. State Street Corp now owns 1,420,595 shares of the specialty pharmaceutical company’s stock valued at $1,676,000 after purchasing an additional 34,790 shares during the last quarter. Institutional investors own 19.45% of the company’s stock.

ACRX stock opened at $1.22 on Wednesday. The stock has a market cap of $113.81 million, a P/E ratio of -1.97 and a beta of 1.86. The firm has a 50 day simple moving average of $1.22 and a 200 day simple moving average of $1.27. AcelRx Pharmaceuticals has a 52 week low of $0.70 and a 52 week high of $2.80.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Read More: Trading based on a resistance level

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.